Opioid Analgesics Market
Hospital Pharmacies to be the Key Revenue Channel for Opioid Analgesics Market. Get Key Facts with FMI
Opioid Analgesics Market By Drug Class, Indication, Route of Administration, End User, Region - Forecast 2022-2032
Opioid Analgesics Market Outlook (2022-2032)
[306 Pages Report] According to a recent assessment by Future Market Insights (FMI), the opioid analgesics market is slated to expand at a 5.4% CAGR, attaining a worth of US$ 41.11 Billion in 2022. Soaring demand for post-surgery pain management and advancements in drug formulations to reduce analgesic side effects are predicted to propel sales of opioid analgesics over the forecast period.
Morphin sales are expected to command 13% of the overall opioid analgesics market share, with a market valuation of US$ 69.55 billion in 2032, according to FMI.
|
Attributes |
Details |
|
Opioid Analgesics Market CAGR (2022-2032) |
5.4% |
|
Opioid Analgesics Market Size (2022) |
US$ 41.11 Billion |
|
Opioid Analgesics Market Size (2030) |
US$ 62.61 Billion |
|
Opioid Analgesics Market Size (2032) |
US$ 69.55 billion |
Let us know your requirement to get
100% FREE customization
The Opioid Analgesics Key Determinants - Creating Hype
Opioid analgesics are widely ideal drugs for pain management and palliative care due to their convenience and efficacy. However, in order to reduce the risk of addiction and overuse, definite restrictions on opioid sales are in place.
As a result, manufacturers are trying to enhance their product offerings by investing in research and development to develop milder and less addictive drugs. This points to lucrative opioid analgesics market growth opportunities for key opioid analgesics manufacturers.
The Valuable Opportunities for Market Makers in the Couple of years
On the other hand, many people believe that smaller doses of opioids are ineffective in alleviating severe pain. These patients require a higher dose of drugs to relieve their pain, which leads inevitably to opioid tolerance and, in some cases, addiction to these drugs.
One of the primary opportunities for opioid analgesics market manufacturers in the opioid drugs market is expected to be the commercialization of opioid-tolerant drugs. This will help to reduce the side effects caused by or associated with high opioid drug consumption, which will boost sales of opioid analgesics in the coming years.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystThe Opioid Analgesics Market's Hurdles
Will the rising prevalence of opioid addiction harm sales?
The primary factors limiting the opioid analgesics market growth are the unavailability of opioids in emerging markets and the side effects associated with these drugs. Aside from that, the escalating magnitude of abusive opioids and their misuse is a major impediment to opioid analgesics market growth.
Furthermore, chronic opioid side effects pose a significant barrier to the market growth. Due to the increased abuse of addictive opioids, physicians have scaled back their prescription for pain management, resulting in a decrease in global sales. The rising prevalence of opioid abuse is expected to stifle opioid analgesics market growth, as practitioners are hesitant to prescribe opioids as a pain reliever.
Comparative View of Adjacent Opioid Analgesics Market
Opioid Analgesics Market:
|
Attributes |
Opioid Analgesics Market |
|
CAGR (2022-2032) |
5.4% |
|
Market Value (2027) |
US$ 53.47 Billion |
|
Growth Factor |
A significant driver for the market is the rising prevalence of orthopaedic diseases, cancer, and chronic pain among the geriatric population. |
|
Opportunity |
The Opioid Analgesics Market is being fueled by rising healthcare costs and rising disposable income. |
|
Key Trends |
It is anticipated that the primary opportunities for manufacturers in the opioid drug market will be the commercialization of opioid-tolerant drugs. |
Pain Management Drugs Market:
|
Attributes |
Pain Management Drugs Market |
|
CAGR (2022-2032) |
3.8% |
|
Market Value (2027) |
US $91,649.16 million |
|
Growth Factor |
The growing geriatric population is a major driver of the global pain management drugs market, as older people are more likely to suffer from joint pain and other chronic conditions. |
|
Opportunity |
The increase in the number of surgical procedures and the increase in healthcare spending are expected to drive the growth of the pain management drugs market. |
|
Key Trends |
The rising prevalence of chronic diseases such as cancer, diabetic neuropathy, and osteoarthritis drives market expansion. |
Opioid Use Disorder Market:
|
Attributes |
Opioid Use Disorder Market |
|
CAGR (2022-2032) |
11.5% |
|
Market Value (2027) |
US$ 5.38 Billion |
|
Growth Factor |
The increase in the prevalence of chronic diseases is expected to drive the growth of the global opioid use disorder market. |
|
Opportunity |
The increase in product launch and approval for opioid use disorder drugs is expected to fuel the growth of the opioid use disorder market. |
|
Key Trends |
The anticipated rise in the prevalence of chronic diseases fuels the demand for opioid use disorder drugs, boosting market growth. |
A unified Market Research Subscription Platform, built for today's disparate research needs.
Which is the Leading Segment in the Opioid Analgesics Market by Drug Class?
According to the drug class, oxycodone is expected to account for 19.4% of the opioid analgesics market. Oxycodone is one of the most potent pain relievers on the market. The medication effectively relieves pain and allows patients to go about their daily activities.
Previously, oxycodone was not widely used due to a lack of knowledge about the constituents and the high cost of drugs. The rising awareness about the benefits of oxycodone, such as increased bioavailability, is encouraging the drug's use.
Which is the Leading Segment in the Opioid Analgesics Market by Indication?
Due to the rising number of surgical procedures and the increasing incidence of associated post-operative pain, the surgical pain indication is expected to account for 45.9% of the opioid analgesics market share.
Opioid analgesics are used as an effective treatment for pain management following an operation or surgery. Over the forecast period, increased adoption of medications for pain management and relief is expected to drive demand for opioid analgesics.
Which is the Leading Segment in the Opioid Analgesics Market by Route of Administration?
The hospital pharmacies are expected to account for 33.1% of the total opioid analgesics market share. Hospitals are major care facilities with a large presence of well-trained staff and professionals who assist patients in receiving effective treatment. Adoption of prescribed therapy in clinics and hospitals aids in physician-supervised drug delivery. This is one of the primary factors driving sales of opioid analgesics through hospital pharmacies.
Regions of High Interest in the Opioid Analgesics Market
What Renders the United States an Enticing Opioid Analgesics Market?
The United States is expected to dominate the North American opioid analgesics market, accounting for 86% of the opioid analgesics market. The rising prevalence of chronic illnesses, as well as the growing adoption of opioid analgesics as a pain reliever, is expected to continue to boost sales of opioid analgesics.
Key opioid analgesic manufacturers in the United States are focusing on launching new products to comply with updated regulatory procedures. Furthermore, government-led investments in clinical research will enable the country to maintain its dominance over the forecast period.
What is the Demand Perspective for Opioid Analgesics in Germany?
In Germany, sales of opioid analgesics are expected to grow at a 3.8% CAGR, reaching a valuation of US$ 2.2 billion in 2021.
Adoption of opioid maintenance treatment (OMT) for the treatment of opioid dependence (OD), increased use of non-abusive opioids, and favourable reimbursement programmes offered by German regulatory bodies regarding awareness of palliative care are key factors driving sales of opioid analgesics in Germany.
Maddening Buzz about Opioid Analgesics Recorded in United Kingdom
The United Kingdom is expected to lead the European opioid analgesics market, with sales increasing at a 4.7% CAGR during the forecast period.
The healthcare system in the United Kingdom is well-known and universal, with significant government funding. It is widely regarded as having one of the most thriving and successful healthcare systems in the world.
The United Kingdom is the third-largest opioid analgesics market, and this position is expected to be maintained throughout the forecast period. Furthermore, the presence of several major players, expanding pipeline drugs, and increasing research efforts create lucrative opioid analgesics market opportunities in the United Kingdom.
Why is China perceived as an emerging country for opioid analgesics?
China is expected to lead the East Asian market in 2021, accounting for 54.2% of the opioid analgesics market share. Due to increasing use of large amounts of opioids for pain management and its extensive manufacturing capacity, China dominates the East Asian market.
Due to rapid productivity and large-scale capital investments in the healthcare sector, China is the world's second-largest pharmaceutical market.
How will India's sales of opioid analgesics fare?
India is anticipated to account for 35.4% of the South Asian market for opioid analgesics, with sales increasing at a steady 5.7% CAGR.
Due to the nation's rising need for opioid analgesics, both small and large pharmaceutical companies in India are actively funding research and development. Many innovative drugs in the funnel are mostly finished and will be made accessible to patients soon.
Clinical trials for opioid analgesics are made possible by the existence of government-funded healthcare and pharmaceutical institutions in India. In the upcoming years, it is anticipated that the increase in research activities underway in India will fuel the opioid analgesics market growth.
What is the State of the Start-up Ecosystem in the Opioid Analgesics Market?
- Novaremed
With the addition of two complementary development initiatives, the acquisition of Metys expands Novaremed's pipeline of novel, non-opioid development candidates for chronic pain indications.
With the addition of chemotherapy-induced peripheral neuropathy (CIPN) to its current focus on excruciating diabetic peripheral neuropathy, Novaremed's pipeline expansion enables it to target a wider segment of neuropathic pain indications (PDPN).
- Pharmachal
Turning Point Therapeutics, Inc. was successfully acquired by Bristol Myers Squibb in an all-cash deal, the company announced. Turning Point is now a fully owned subsidiary of Bristol Myers Squibb after the acquisition was finalised, and shares of Turning Point no longer trade on the NASDAQ Global Select Market.
- AntalGenics
AntalGenics, a Spanish start-up, created novel molecules to treat chronic pain. The start-up is currently looking into two molecules, AG1529 and AG1531, to treat osteoarthritis pain and psoriatic pruritus. Additionally, the startup creates cosmetic active ingredients for skin and scalp sensitivity.
At in-cosmetics Virtual 2020, AntalGenics will introduce two of its cutting-edge neurocosmetic ingredients: Capsisilence, which promotes a healthy scalp, and Calmapsin, which lessens the signs of sensitive skin.
- InnoPain
A drug to mimic the effects of morphine without the negative side effects is being developed by the French startup InnoPain. The analgesic effect of morphine is produced by an interaction between the startup's lead candidate, TREK-1, and the -opioid receptor (OR). The startup is also working on RNE28, a brand-new class of oral and intravenous analgesic medications.
- Neumentum
The pharmaceutical company Neumentum has raised $6 million in a Series A funding round by selling Series A Convertible Preferred Stock. Neumentum is committed to revolutionising the way acute and chronic pain is treated without the use of opioids. The sole placement agent for the financing was Brookline Capital Markets.
How Does Intensity of Rivalry Affect the Opioid Analgesics Market?
Crucial players are trying to emphasize product portfolio expansion by launching new and updated products in emerging opioid analgesics market. Players in the market for opioid analgesics are anticipated to benefit from product approvals, agreements, partnerships, facility expansion, and strategic collaborations to achieve a competitive advantage.
Pfizer Inc, Abbott Laboratories, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Bayer AG, GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Boehringer Ingelheim International GmbH, Bausch Health Companies Inc., and Sanofi S.A. are some of the significant players operating in market for opioid analgesics.
Recent Development
| Date | May 2020 |
| Company | Assertio Therapeutics, Inc. |
| Strategy | Merger |
| Details | Assertio Therapeutics, Inc. will merge with Zyla Life Sciences. The merger enabled the companies to broaden their product portfolios in neurology, inflammation, and chronic pain. |
| Date | September 2021 |
| Company | Bausch Health Companies Inc. |
| Strategy | Data |
| Details | Bausch Health Companies Inc. and its gastroenterology business, Salix, will present RELISTOR® (Methylnaltrexone Bromide) data at PAINWeek 2021. The opioid antagonist RELISTOR® (methylnaltrexone bromide) RELISTOR tablets and RELISTOR injection are approved to treat opioid-induced constipation (OIC) in adults suffering from chronic non-cancer pain. |
| Date | August 08, 2022 |
| Company | Global Blood Therapeutics, Inc. (GBT) |
| Strategy | Agreement |
| Details | Global Blood Therapeutics, Inc. (GBT), and Pfizer Inc., announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT (SCD). |
| Date | August 23, 2022 |
| Company | F. Hoffmann-La Roche AG |
| Strategy | Introduction |
| Details | In the fight against cancer and other diseases, Roche introduces a powerful new diagnostics platform called the digital PCR system. |
| Date | January 2020 |
| Company | Allergan PLC |
| Strategy | Product Launch |
| Details | The new drug application that Allergan PLC submitted in January 2020 has been approved by the FDA. The application was made by a business called DURYSTA for the Food and Drug Administration. It is the first of its kind and aims to lower intraocular pressure by giving sustained-release, biodegradable medication. Due to open-angle glaucoma and ocular hypertension (OHT), this is possible. |
| Date | December 1st, 2019 |
| Company | Veritas Pharma Inc |
| Strategy | Collaboration |
| Details | The FDA disclosed that the Prescription Drug User Fee Act (PDUFA) would go into effect on December 1st, 2019, at Veritas Pharma Inc. In 2020, Daiichi Sankyo declared that it would collaborate with Ultragenyx Pharmaceutical to enhance research. |
Key Players
- Pfizer Inc.
- Abbott Laboratories
- Janssen Pharmaceuticals, Inc. [Johnson & Johnson]
- Novartis AG
- Bayer AG
- GlaxoSmithKline plc
- F. Hoffmann-La Roche AG,
- Boehringer Ingelheim International GmbH
- Bausch Health Companies Inc.
- Sanofi S.A.
- Teva Pharmaceuticals
- AbbVie Inc. (Allergan plc)
- Purdue Pharmaceuticals L.P.
- Sun Pharmaceutical Industries Ltd.
- Mallinckrodt Pharmaceuticals
- Endo Pharmaceuticals Inc. [Endo International plc]
- Assertio Therapeutics, Inc. [Assertio Holdings, Inc.]
Key Segments
By Drug Class:
- Morphine
- Codeine
- Fentanyl
- Meperidine
- Methadone
- Tramadol
- Oxycodone
- Dextromethorphan
- Buprenorphine
- Others
By Indication:
- Surgical Pain
- Cancer Pain
- Neuropathic Pain
- Other
By Route of Administration:
- Oral
- Parenteral
- Transdermal
- Other
By End User:
- Hospitals
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- MEA
Frequently Asked Questions
The opioid analgesics market is predicted to grow at 5.4% CAGR through 2032.
Asia Pacific opioid analgesics market holds the highest revenue potential.
The opioid analgesics market size is anticipated to be over US$ 41.11 Billion in 2022.
The market for opioid analgesics is expected to surpass US$ 69.55 billion by 2032.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Market Context
4.1. Drug Adoption / Usage Analysis
4.2. Key Strategies Adopted By Manufactures
4.3. Regulatory Scenario
5. Key Inclusion
5.1. Drug Adoption / Usage Analysis
5.2. Key Strategies Adopted By Manufactures
5.3. Regulatory Scenario
6. Market Background
6.1. Macro-Economic Factors
6.1.1. Global GDP Growth Outlook
6.1.2. Global Healthcare Outlook
6.2. Forecast Factors - Relevance & Impact
6.2.1. Increasing Prevalence of Chronic Disease and Surgical Procedures
6.2.2. Increasing Prevalence of Neuropathic and Chronic pain
6.2.3. Elevating Awareness about Palliative Care and Pain Management
6.3. Market Dynamics
6.3.1. Drivers
6.3.2. Restraints
6.3.3. Opportunity Analysis
6.4. Value Chain Analysis
7. COVID19 Crisis Analysis
7.1.1. Current COVID19 Statistics and Probable Future Impact
7.1.2. Current GDP Projection and Probable Impact
7.1.3. Current Economic Projection as compared to 2008 Economic analysis
7.1.4. COVID19 and Impact Analysis
7.1.4.1. Revenue By Product
7.1.4.2. Revenue By Country
8. Global Analgesics Market Demand (in Value or Size in US$ Mn) Analysis 2017-2021 and Forecast, 2022–2032
8.1. Historical Market Value (US$ Mn) Analysis, 2017-2021
8.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032
8.2.1. Y-o-Y Growth Trend Analysis
8.2.2. Absolute $ Opportunity Analysis
9. Global Analgesics Market Analysis 2017-2021 and Forecast 2022–2032, By Drug Class
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2017-2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2022–2032
9.3.1. Morphine
9.3.2. Codeine
9.3.3. Fentanyl
9.3.4. Meperidine
9.3.5. Methadone
9.3.6. Tramadol
9.3.7. Oxycodone
9.3.8. Dextromethorphan
9.3.9. Buprenorphine
9.3.10. Others
10. Global Analgesics Market Analysis 2017-2021 and Forecast 2022–2032, by Indication
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Indication, 2017-2021
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast Indication, 2022 – 2032
10.3.1. Surgical Pain
10.3.2. Cancer Pain
10.3.3. Neuropathic Pain
10.3.4. Other
10.4. Market Attractiveness Analysis By Indications
11. Global Analgesics Market Analysis 2017-2021 and Forecast 2022–2032, by Route of Administration
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2017-2021
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast Route of Administration, 2022–2032
11.3.1. Oral
11.3.2. Parenteral
11.3.3. Transdermal
11.3.4. Others
11.4. Market Attractiveness Analysis By Route of Administration
12. Global Analgesics Market Analysis 2017-2021 and Forecast 2022–2032, by Distribution Channel
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2017-2021
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2022–2032
12.3.1. Hospitals
12.3.2. Retail Pharmacies
12.3.3. Drug Stores
12.3.4. Online Pharmacies
12.4. Market Attractiveness Analysis By Distribution Channel
13. Global Analgesics Market Analysis 2017-2021 and Forecast 2022–2032, by Region
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis By Region, 2017-2021
13.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022–2032
13.3.1. North America
13.3.2. Latin America
13.3.3. Europe
13.3.4. South Asia
13.3.5. East Asia
13.3.6. Oceania
13.3.7. Middle East & Africa
13.4. Market Attractiveness Analysis By Region
14. North America Analgesics Market Analysis 2017-2021 and Forecast 2022–2032
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
14.3.1. By Drug Class
14.3.2. By Indication
14.3.3. By Route of Administration
14.3.4. By Distribution Channel
14.3.5. By Country
14.3.5.1. U.S.
14.3.5.2. Canada
14.4. Market Attractiveness Analysis
14.5. Drivers and Restraints-Impact Analysis
15. Latin America Analgesics Market Analysis 2017-2021 and Forecast 2022–2032
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
15.3.1. By Drug Class
15.3.2. By Indication
15.3.3. By Route of Administration
15.3.4. By Distribution Channel
15.3.5. By Country
15.3.5.1. Brazil
15.3.5.2. Mexico
15.3.5.3. Argentina
15.3.5.4. Rest of Latin America
15.4. Market Attractiveness Analysis
15.5. Drivers and Restraints-Impact Analysis
16. Europe Analgesics Market Analysis 2017-2021 and Forecast 2022–2032
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
16.3.1. By Drug Class
16.3.2. By Indication
16.3.3. By Route of Administration
16.3.4. By Distribution Channel
16.3.5. By Country
16.3.5.1. Germany
16.3.5.2. Italy
16.3.5.3. France
16.3.5.4. U.K.
16.3.5.5. Spain
16.3.5.6. BENELUX
16.3.5.7. Russia
16.3.5.8. Rest of Europe
16.4. Market Attractiveness Analysis
16.5. Drivers and Restraints-Impact Analysis
17. South Asia Analgesics Market Analysis 2017-2021 and Forecast 2022–2032
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
17.3.1. By Drug Class
17.3.2. By Indication
17.3.3. By Route of Administration
17.3.4. By Distribution Channel
17.3.5. By Country
17.3.5.1. India
17.3.5.2. Thailand
17.3.5.3. Indonesia
17.3.5.4. Malaysia
17.3.5.5. Rest of South Asia
17.4. Market Attractiveness Analysis
17.5. Drivers and Restraints-Impact Analysis
18. East Asia Analgesics Market Analysis 2017-2021 and Forecast 2022–2032
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
18.3.1. By Drug Class
18.3.2. By Indication
18.3.3. By Route of Administration
18.3.4. By Distribution Channel
18.3.5. By Country
18.3.5.1. China
18.3.5.2. Japan
18.3.5.3. South Korea
18.4. Market Attractiveness Analysis
18.5. Drivers and Restraints-Impact Analysis
19. Oceania Analgesics Market Analysis 2017-2021 and Forecast 2022–2032
19.1. Introduction
19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
19.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
19.3.1. By Drug Class
19.3.2. By Indication
19.3.3. By Route of Administration
19.3.4. By Distribution Channel
19.3.5. By Country
19.3.5.1. Australia
19.3.5.2. New Zealand
19.4. Market Attractiveness Analysis
19.5. Drivers and Restraints-Impact Analysis
20. Middle East and Africa Analgesics Market Analysis 2017-2021 and Forecast 2022–2032
20.1. Introduction
20.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
20.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
20.3.1. By Drug Class
20.3.2. By Indication
20.3.3. By Route of Administration
20.3.4. By Distribution Channel
20.3.5. By Country
20.3.5.1. GCC Countries
20.3.5.2. Turkey
20.3.5.3. Northern Africa
20.3.5.4. South Africa
20.3.5.5. Rest of Middle East and Africa
20.4. Market Attractiveness Analysis
20.5. Drivers and Restraints-Impact Analysis
21. Key and Emerging Countries Analgesics Market Analysis
21.1. Introduction
21.1.1. Market Value Proportion Analysis, By Key Countries
21.1.2. Global Vs. Country Growth Comparison
21.2. U.S. Analgesics Market Analysis
21.2.1. By Drug Class
21.2.2. By Indication
21.2.3. By Route of Administration
21.2.4. By Distribution Channel
21.3. Canada Analgesics Market Analysis
21.3.1. By Drug Class
21.3.2. By Indication
21.3.3. By Route of Administration
21.3.4. By Distribution Channel
21.4. Mexico Analgesics Market Analysis
21.4.1. By Drug Class
21.4.2. By Indication
21.4.3. By Route of Administration
21.4.4. By Distribution Channel
21.5. Brazil Analgesics Market Analysis
21.5.1. By Drug Class
21.5.2. By Indication
21.5.3. By Route of Administration
21.5.4. By Distribution Channel
21.6. Germany Analgesics Market Analysis
21.6.1. By Drug Class
21.6.2. By Indication
21.6.3. By Route of Administration
21.6.4. By Distribution Channel
21.7. Italy Analgesics Market Analysis
21.7.1. By Drug Class
21.7.2. By Indication
21.7.3. By Route of Administration
21.7.4. By Distribution Channel
21.8. France Analgesics Market Analysis
21.8.1. By Drug Class
21.8.2. By Indication
21.8.3. By Route of Administration
21.8.4. By Distribution Channel
21.9. U.K. Analgesics Market Analysis
21.9.1. By Drug Class
21.9.2. By Indication
21.9.3. By Route of Administration
21.9.4. By Distribution Channel
21.10. Spain Analgesics Market Analysis
21.10.1. By Drug Class
21.10.2. By Indication
21.10.3. By Route of Administration
21.10.4. By Distribution Channel
21.11. BENELUX Analgesics Market Analysis
21.11.1. By Drug Class
21.11.2. By Indication
21.11.3. By Route of Administration
21.11.4. By Distribution Channel
21.12. Russia Analgesics Market Analysis
21.12.1. By Drug Class
21.12.2. By Indication
21.12.3. By Route of Administration
21.12.4. By Distribution Channel
21.13. China Analgesics Market Analysis
21.13.1. By Drug Class
21.13.2. By Indication
21.13.3. By Route of Administration
21.13.4. By Distribution Channel
21.14. Japan Analgesics Market Analysis
21.14.1. By Drug Class
21.14.2. By Indication
21.14.3. By Route of Administration
21.14.4. By Distribution Channel
21.15. South Korea Analgesics Market Analysis
21.15.1. By Drug Class
21.15.2. By Indication
21.15.3. By Route of Administration
21.15.4. By Distribution Channel
21.16. India Analgesics Market Analysis
21.16.1. By Drug Class
21.16.2. By Indication
21.16.3. By Route of Administration
21.16.4. By Distribution Channel
21.17. ASEAN Analgesics Market Analysis
21.17.1. By Drug Class
21.17.2. By Indication
21.17.3. By Route of Administration
21.17.4. By Distribution Channel
21.18. Australia Analgesics Market Analysis
21.18.1. By Drug Class
21.18.2. By Indication
21.18.3. By Route of Administration
21.18.4. By Distribution Channel
21.19. New Zealand Analgesics Market Analysis
21.19.1. By Drug Class
21.19.2. By Indication
21.19.3. By Route of Administration
21.19.4. By Distribution Channel
21.20. GCC Countries Analgesics Market Analysis
21.20.1. By Drug Class
21.20.2. By Indication
21.20.3. By Route of Administration
21.20.4. By Distribution Channel
21.21. Turkey Analgesics Market Analysis
21.21.1. By Drug Class
21.21.2. By Indication
21.21.3. By Route of Administration
21.21.4. By Distribution Channel
21.22. South Africa Analgesics Market Analysis
21.22.1. By Drug Class
21.22.2. By Indication
21.22.3. By Route of Administration
21.22.4. By Distribution Channel
22. Market Structure Analysis
22.1. Market Share Analysis
22.2. Market Analysis by Tier of Companies
22.3. Market Concentration
23. Competition Analysis
23.1. Competition Dashboard
23.2. Competition Deep Dive
23.2.1. Pfizer Inc.
23.2.1.1. Overview
23.2.1.2. Product Offering
23.2.1.3. Regional Footprint
23.2.1.4. Strategy Overview
23.2.1.4.1. Marketing Strategy
23.2.1.4.2. Product Strategy
23.2.1.4.3. Channel Strategy
23.2.2. Sun Pharmaceutical Industries, Inc.
23.2.2.1. Overview
23.2.2.2. Product Offering
23.2.2.3. Regional Footprint
23.2.2.4. Strategy Overview
23.2.2.4.1. Marketing Strategy
23.2.2.4.2. Product Strategy
23.2.2.4.3. Channel Strategy
23.2.3. Sanofi SA
23.2.3.1. Overview
23.2.3.2. Product Offering
23.2.3.3. Regional Footprint
23.2.3.4. Strategy Overview
23.2.3.4.1. Marketing Strategy
23.2.3.4.2. Product Strategy
23.2.3.4.3. Channel Strategy
23.2.4. AbbVie Inc. (Allergan plc)
23.2.4.1. Overview
23.2.4.2. Product Offering
23.2.4.3. Regional Footprint
23.2.4.4. Strategy Overview
23.2.4.4.1. Marketing Strategy
23.2.4.4.2. Product Strategy
23.2.4.4.3. Channel Strategy
23.2.5. Teva Pharmaceuticals
23.2.5.1. Overview
23.2.5.2. Product Offering
23.2.5.3. Regional Footprint
23.2.5.4. Strategy Overview
23.2.5.4.1. Marketing Strategy
23.2.5.4.2. Product Strategy
23.2.5.4.3. Channel Strategy
23.2.6. Boehringer Ingelheim International GmbH
23.2.6.1. Overview
23.2.6.2. Product Offering
23.2.6.3. Regional Footprint
23.2.6.4. Strategy Overview
23.2.6.4.1. Marketing Strategy
23.2.6.4.2. Product Strategy
23.2.6.4.3. Channel Strategy
23.2.7. Janssen Pharmaceuticals, Inc. [Johnson & Johnson]
23.2.7.1. Overview
23.2.7.2. Product Offering
23.2.7.3. Regional Footprint
23.2.7.4. Strategy Overview
23.2.7.4.1. Marketing Strategy
23.2.7.4.2. Product Strategy
23.2.7.4.3. Channel Strategy
23.2.8. Endo Pharmaceuticals Inc.
23.2.8.1. Overview
23.2.8.2. Product Offering
23.2.8.3. Regional Footprint
23.2.8.4. Strategy Overview
23.2.8.4.1. Marketing Strategy
23.2.8.4.2. Product Strategy
23.2.8.4.3. Channel Strategy
23.2.9. Purdue Pharmaceuticals L.P.
23.2.9.1. Overview
23.2.9.2. Product Offering
23.2.9.3. Regional Footprint
23.2.9.4. Strategy Overview
23.2.9.4.1. Marketing Strategy
23.2.9.4.2. Product Strategy
23.2.9.4.3. Channel Strategy
23.2.10. Assertio Therapeutics, Inc.
23.2.10.1. Overview
23.2.10.2. Product Offering
23.2.10.3. Regional Footprint
23.2.10.4. Strategy Overview
23.2.10.4.1. Marketing Strategy
23.2.10.4.2. Product Strategy
23.2.10.4.3. Channel Strategy
23.2.11. Mallinckrodt Pharmaceuticals
23.2.11.1. Overview
23.2.11.2. Product Offering
23.2.11.3. Regional Footprint
23.2.11.4. Strategy Overview
23.2.11.4.1. Marketing Strategy
23.2.11.4.2. Product Strategy
23.2.11.4.3. Channel Strategy
23.2.12. Bayer AG
23.2.12.1. Overview
23.2.12.2. Product Offering
23.2.12.3. Regional Footprint
23.2.12.4. Strategy Overview
23.2.12.4.1. Marketing Strategy
23.2.12.4.2. Product Strategy
23.2.12.4.3. Channel Strategy
23.2.13. GlaxoSmithKline plc.
23.2.13.1. Overview
23.2.13.2. Product Offering
23.2.13.3. Regional Footprint
23.2.13.4. Strategy Overview
23.2.13.4.1. Marketing Strategy
23.2.13.4.2. Product Strategy
23.2.13.4.3. Channel Strategy
23.2.14. Bausch Health Companies Inc.
23.2.14.1. Overview
23.2.14.2. Product Offering
23.2.14.3. Regional Footprint
23.2.14.4. Strategy Overview
23.2.14.4.1. Marketing Strategy
23.2.14.4.2. Product Strategy
23.2.14.4.3. Channel Strategy
23.2.15. Novartis AG
23.2.15.1. Overview
23.2.15.2. Product Offering
23.2.15.3. Regional Footprint
23.2.15.4. Strategy Overview
23.2.15.4.1. Marketing Strategy
23.2.15.4.2. Product Strategy
23.2.15.4.3. Channel Strategy
23.2.16. Others
23.2.16.1. Overview
23.2.16.2. Product Offering
23.2.16.3. Regional Footprint
23.2.16.4. Strategy Overview
23.2.16.4.1. Marketing Strategy
23.2.16.4.2. Product Strategy
23.2.16.4.3. Channel Strategy
24. Assumptions and Acronyms Used
25. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Expenditure on Health, (% of GDP), by Country, 2017 - 2022
Table 02: Expenditure on Health, (% of GDP), by Country, 2017 - 2022
Table 03: Global Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Drug Class
Table 04: Global Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication
Table 05: Global Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
Table 06: Global Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
Table 07: Global Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Region
Table 08: North America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country
Table 09: North America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Drug Class
Table 10: North America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication
Table 11: North America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
Table 12: North America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
Table 13: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country
Table 14: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Drug Class
Table 15: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication
Table 16: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
Table 17: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
Table 18: Europe Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country
Table 19: Europe Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Drug Class
Table 20: Europe Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication
Table 21: Europe Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
Table 22: Europe Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
Table 23: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country
Table 24: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Drug Class
Table 25: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication
Table 26: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
Table 27: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
Table 28: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country
Table 29: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Drug Class
Table 30: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication
Table 31: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
Table 32: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
Table 33: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country
Table 34: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Drug Class
Table 35: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication
Table 36: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
Table 37: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
Table 38: MEA Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Country
Table 39: MEA Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Drug Class
Table 40: MEA Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication
Table 41: MEA Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
Table 42: MEA Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01 : Global Opioid Analgesics Market Value (US$ Mn) Forecast, 2022 – 2032
Figure 02 : Global Opioid Analgesics Market Share, By Drug Class (2022)
Figure 03 : Global Opioid Analgesics Market Share, By Region (2022)
Figure 04: Global Opioid Analgesics Market Size (US$ Mn) Analysis, 2017-2021
Figure 05: Global Opioid Analgesics Market Size (US$ Mn) & Y-o-Y Growth (%) Analysis, 2022-2032
Figure 06: Global Opioid Analgesics Market Absolute $ Opportunity Analysis, 2022-2032
Figure 07: Global Opioid Analgesics Market Analysis By Drug Class–2022 & 2032
Figure 08: Global Opioid Analgesics Market Y-o-Y Growth Projections By Drug Class, 2022-2032
Figure 09: Global Opioid Analgesics Market Attractiveness, By Drug Class
Figure 10: Global Opioid Analgesics Market Analysis By Indication–2022 & 2032
Figure 11: Global Opioid Analgesics Market Y-o-Y Growth Projections By Indication, 2022-2032
Figure 12: Global Opioid Analgesics Market Attractiveness, By Indication
Figure 13: Global Opioid Analgesics Market Analysis By Route of Administration – 2022 & 2032
Figure 14: Global Opioid Analgesics Market Y-o-Y Growth Projections By Route of Administration, 2022-2032
Figure 15: Global Opioid Analgesics Market Attractiveness, By Route of Administration
Figure 16: Global Opioid Analgesics Market Analysis By Distribution Channel–2022 & 2032
Figure 17: Global Opioid Analgesics Market Y-o-Y Growth Projections By Distribution Channel, 2022-2032
Figure 18: Global Opioid Analgesics Market Attractiveness, By Distribution Channel
Figure 19: Global Opioid Analgesics Market Analysis by Region–2022 & 2032
Figure 20: Global Opioid Analgesics Market Y-o-Y Growth Projections by Region, 2022-2032
Figure 21: Global Opioid Analgesics Market Attractiveness, By Region
Figure 22: North America Opioid Analgesics Market Share, By Drug Class, 2022 (E)
Figure 23: North America Opioid Analgesics Market Share, By Indication, 2022 (E)
Figure 24: North America Opioid Analgesics Market Share, By Route of Administration, 2022 (E)
Figure 25: North America Opioid Analgesics Market Share, By Distribution Channel, 2022 (E)
Figure 26: North America Opioid Analgesics Market Share, By Country, 2022 (E)
Figure 27: North America Opioid Analgesics Market Size (US$ Mn) Analysis, 2017-2021
Figure 28: North America Opioid Analgesics Market Size (US$ Mn) & Y-o-Y Growth (%), 2022-2032
Figure 29: North America Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Country
Figure 30: North America Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Drug Class
Figure 31: North America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication
Figure 32: North America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
Figure 33: North America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
Figure 34: Latin America Opioid Analgesics Market Share, By Drug Class, 2022 (E)
Figure 35: Latin America Opioid Analgesics Market Share, By Indication, 2022 (E)
Figure 36: Latin America Opioid Analgesics Market Share, By Route of Administration, 2022 (E)
Figure 37: Latin America Opioid Analgesics Market Share, By Distribution Channel, 2022 (E)
Figure 38: Latin America Opioid Analgesics Market Share, By Country, 2022 (E)
Figure 39: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis, 2017-2021
Figure 40: Latin America Opioid Analgesics Market Size (US$ Mn) & Y-o-Y Growth (%), 2022-2032
Figure 41: Latin America Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Country
Figure 42: Latin America Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Drug Class
Figure 43: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication
Figure 44: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
Figure 45: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
Figure 46: Europe Opioid Analgesics Market Share, By Drug Class, 2022 (E)
Figure 47: Europe Opioid Analgesics Market Share, By Indication, 2022 (E)
Figure 48: Europe Opioid Analgesics Market Share, By Route of Administration, 2022 (E)
Figure 49: Europe Opioid Analgesics Market Share, By Distribution Channel, 2022 (E)
Figure 50: Europe Opioid Analgesics Market Share, By Country, 2022 (E)
Figure 51: Europe Opioid Analgesics Market Size (US$ Mn) Analysis, 2017-2021
Figure 52: Europe Opioid Analgesics Market Size (US$ Mn) & Y-o-Y Growth (%), 2022-2032
Figure 53: Europe Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Country
Figure 54: Europe Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Drug Class
Figure 55: Europe Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication
Figure 56: Europe Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
Figure 57: Europe Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
Figure 58: South Asia Opioid Analgesics Market Share, By Drug Class, 2022 (E)
Figure 59: South Asia Opioid Analgesics Market Share, By Indication, 2022 (E)
Figure 60: South Asia Opioid Analgesics Market Share, By Route of Administration, 2022 (E)
Figure 61: South Asia Opioid Analgesics Market Share, By Distribution Channel, 2022 (E)
Figure 62: South Asia Opioid Analgesics Market Share, By Country, 2022 (E)
Figure 63: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis, 2017-2021
Figure 64: South Asia Opioid Analgesics Market Size (US$ Mn) & Y-o-Y Growth (%), 2022-2032
Figure 65: South Asia Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Country
Figure 66: South Asia Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Drug Class
Figure 67: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication
Figure 68: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
Figure 69: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
Figure 70: East Asia Opioid Analgesics Market Share, By Drug Class, 2022 (E)
Figure 71: East Asia Opioid Analgesics Market Share, By Indication, 2022 (E)
Figure 72: East Asia Opioid Analgesics Market Share, By Route of Administration, 2022 (E)
Figure 73: East Asia Opioid Analgesics Market Share, By Distribution Channel, 2022 (E)
Figure 74: East Asia Opioid Analgesics Market Share, By Country, 2022 (E)
Figure 75: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis, 2017-2021
Figure 76: East Asia Opioid Analgesics Market Size (US$ Mn) & Y-o-Y Growth (%), 2022-2032
Figure 77: East Asia Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Country
Figure 78: East Asia Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Drug Class
Figure 79: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication
Figure 80: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
Figure 81: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
Figure 82: Oceania Opioid Analgesics Market Share, By Drug Class, 2022 (E)
Figure 83: Oceania Opioid Analgesics Market Share, By Indication, 2022 (E)
Figure 84: Oceania Opioid Analgesics Market Share, By Route of Administration, 2022 (E)
Figure 85: Oceania Opioid Analgesics Market Share, By Distribution Channel, 2022 (E)
Figure 86: Oceania Opioid Analgesics Market Share, By Country, 2022 (E)
Figure 87: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis, 2017-2021
Figure 88: Oceania Opioid Analgesics Market Size (US$ Mn) & Y-o-Y Growth (%), 2022-2032
Figure 89: Oceania Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Country
Figure 90: Oceania Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Drug Class
Figure 91: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication
Figure 92: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
Figure 93: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
Figure 94: MEA Opioid Analgesics Market Share, By Drug Class, 2022 (E)
Figure 95: MEA Opioid Analgesics Market Share, By Indication, 2022 (E)
Figure 96: MEA Opioid Analgesics Market Share, By Route of Administration, 2022 (E)
Figure 97: MEA Opioid Analgesics Market Share, By Distribution Channel, 2022 (E)
Figure 98: MEA Opioid Analgesics Market Share, By Country, 2022 (E)
Figure 99: MEA Opioid Analgesics Market Size (US$ Mn) Analysis, 2017-2021
Figure 100: MEA Opioid Analgesics Market Size (US$ Mn) & Y-o-Y Growth (%), 2022-2032
Figure 101: MEA Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Country
Figure 102: MEA Opioid Analgesics Market Attractiveness Analysis 2022-2032 By Drug Class
Figure 103: MEA Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Indication
Figure 104: MEA Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
Figure 105: MEA Opioid Analgesics Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
Figure 106: Global Opioid Analgesics Market Value Proportion Analysis, By Emerging Countries, 2021
Figure 107: Opioid Analgesics Market, Global Vs. Country Growth Y-o-Y (%) Comparison, 2022-2032
Figure 108: U.S. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 109: U.S. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032
Figure 110: U.S. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032
Figure 111: U.S. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 112: Canada Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 113: Canada Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032
Figure 114: Canada. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032
Figure 115: Canada. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 116: Brazil. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 117: Brazil. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032
Figure 118: Brazil. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032
Figure 119: Brazil. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 120: Mexico. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 121: Mexico. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032
Figure 122: Mexico. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032
Figure 123: Mexico. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 124: UK. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 125: UK. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032
Figure 126: UK. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032
Figure 127: UK. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 128: Germany. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 129: Germany. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032
Figure 130: Germany. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032
Figure 131: Germany. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 132: Italy. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 133: Italy. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032
Figure 134: Italy. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032
Figure 135: Italy. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 136: France. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 137: France. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032
Figure 138: France. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032
Figure 139: France. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 140: Spain. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 141: Spain. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032
Figure 142: Spain. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032
Figure 143: Spain. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 144: Russia. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 145: Russia. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032
Figure 146: Russia. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032
Figure 147: Russia. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 148: BENELUX Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 149: BENELUX Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032
Figure 150: BENELUX Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032
Figure 151: BENELUX Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 152: China. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 153: China. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032
Figure 154: China. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032
Figure 155: China. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 156: Japan. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 157: Japan. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032
Figure 158: Japan. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032
Figure 159: Japan. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 160: South Korea. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 161: South Korea. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032
Figure 162: South Korea. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032
Figure 163: South Korea. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 164: India. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 165: India. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032
Figure 166: India. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032
Figure 167: India. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 168: Thailand. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 169: Thailand. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032
Figure 170: Thailand. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032
Figure 171: Thailand. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 172: Indonesia. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 173: Indonesia. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032
Figure 174: Indonesia. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032
Figure 175: Indonesia. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 176: Malaysia. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 177: Malaysia. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032
Figure 178: Malaysia. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032
Figure 179: Malaysia. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 180: Australia. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 181: Australia. Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032
Figure 182: Australia. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032
Figure 183: Australia. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 184: New Zealand Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 185: New Zealand Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032
Figure 186: New Zealand Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032
Figure 187: New Zealand Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 188: Turkey Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 189: Turkey Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032
Figure 190: Turkey Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032
Figure 191: Turkey Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 192: GCC Countries Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 193: GCC Countries Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032
Figure 194: GCC Countries Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032
Figure 195: GCC Countries Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Figure 196: South Africa Opioid Analgesics Market Share Analysis (%) By Drug Class, 2022 & 2032
Figure 197: South Africa Opioid Analgesics Market Share Analysis (%) By Indication, 2022 & 2032
Figure 198: South Africa Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2022 & 2032
Figure 199: South Africa Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2022 & 2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
